Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 1;13(6):1034-1037.
doi: 10.21037/hbsn-24-568. Epub 2024 Nov 14.

Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease

Isabella Lurje  1   2 , Frank Tacke  1
Affiliations
Editorial

Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease

Isabella Lurje et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Metabolic dysfunction-associated steatotic liver disease (MASLD); metabolic dysfunctionassociated steatohepatitis (MASH); non-alcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); thyroid receptors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-24-568/coif). F.T. serves as an unpaid editorial board member of HepatoBiliary Surgery and Nutrition. F.T. reports research funding from AstraZeneca, MSD, Gilead, Agomab (fundings to his institution); consulting fees from AstraZeneca, Gilead, GSK, Abbvie, BMS, Intercept, Ipsen, Pfizer, Novartis, Novo Nordisk, MSD, Sanofi, Boehringer; payment or honoraria from Gilead, AbbVie, Falk, Merz, Intercept, Sanofi, Astra Zeneca, Orphalan, Boehringer; support for attending meetings and/or travel from Gilead; participation in Advisory Boards from Sanofi and Pfizer. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Trial design of the MAESTRO-NAFLD-1 trial. The MAESTRO-NAFLD-1 (NCT04197479) trial [adapted from (7)] randomized patients to three double-blind arms. Treatment-emergent adverse events constituted the primary endpoint, metabolic and hepatic readouts were the secondary endpoints. Given numbers represent randomized subjects. Figure created with Biorender.com. 1, non-invasive testing for screening; 2, selected secondary outcomes are depicted. LDL-C, low-density lipoprotein-cholesterol.
Figure 2
Figure 2
Effects of Resmetirom, as reported by the MAESTRO-NAFLD-1 trial. Only selected effects from the study (7) are depicted. Figure created with Biorender.com. BP, blood pressure; FT3, free triiodothyronine; FT4, free thyroxine; HDL, high density lipoprotein; MASLD, metabolic dysfunction-associated steatotic liver disease; RLP, remnant-like particle; SHBG, sex hormone-binding globulin; TSH, thyroid-stimulating hormone; VLDL, very low-density lipoprotein.
See this image and copyright information in PMC

Comment on

References

    1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7:851-61. 10.1016/S2468-1253(22)00165-0 - DOI - PubMed
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO); EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024;81:492-542. 10.1016/j.jhep.2024.04.031 - DOI - PubMed
    1. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021;384:1113-24. 10.1056/NEJMoa2028395 - DOI - PubMed
    1. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024;390:497-509. 10.1056/NEJMoa2309000 - DOI - PubMed
    1. Chen YL, Tian S, Wu J, et al. Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease. J Clin Endocrinol Metab 2023;108:e434-43. 10.1210/clinem/dgad016 - DOI - PubMed

LinkOut - more resources